Literature DB >> 18534548

Cytokines, chemokine receptors, CD4+CD25HIGH+ T-cells and clinical forms of human schistosomiasis.

Andréa Teixeira-Carvalho1, Olindo Assis Martins-Filho, Vanessa Peruhype-Magalhães, Denise Silveira-Lemos, Luiz Cosme Cotta Malaquias, Lúcia Fraga Alves Oliveira, Alda Maria Soares Silveira, Andréa Gazzinelli, Giovanni Gazzinelli, Rodrigo Corrêa-Oliveira.   

Abstract

Previous studies have demonstrated that distinct immune response profiles can be correlated with the development/maintenance of different clinical forms of human schistosomiasis. We have previously shown that individuals with the more severe clinical forms of the disease such as those presenting different levels of fibrosis or with the hepatosplenic (HS) clinical form of the disease show significantly different immune response when compared with those with the intestinal clinical form (INT). To better understand the immune mechanisms associated with the clinical form of the schistosomiasis, in this study, we present the results of the evaluation, at a single cell level, of the cytokine patterns as well as the chemokine receptors expression by T-cell subsets after in vitro short-term stimulation with soluble egg antigens as well as the ex vivo frequency analysis of putative regulatory CD4+CD25HIGH+ T-cell subset in the peripheral blood mononuclear cells. We observed an increase on IL-4+, IL-5+ and IL-10+ cells both in the CD4+ and CD8+ lymphocytes in INT and a significant decrease on the number of IL-4+, IL-5+ and IL-10+ T-lymphocytes for HS. However, patients with detectable fibrosis presented decrease on IL-10+ (both CD4+ and CD8+ lymphocytes) and basal levels of IL-4 and IL-5. These data suggested that although INT group is under the influence of an effective immunoregulated immune response, mainly due to the high percentage of IL-10+ cells, it presents a mixed type (Type1/Type-2) immune profile. Moreover, the chemokine receptors expression demonstrated that CXCR3 and CXCR4 by CD4+ T-cells in INT may dictate the selective profile of IL-10 associated with the immunomodulatory events in human schistosomiasis. Additionally, the ex vivo analysis also suggests that higher levels of CD4+CD25HIGH+ T-cells may play a role in controlling morbidity in chronic human schistosomiasis. Taken together, these data suggest a major role of IL-10-producing CXCR4+ CD4+ T-cell subset for the asymptomatic outcome of the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18534548     DOI: 10.1016/j.actatropica.2008.04.010

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  12 in total

1.  Similar cellular responses after treatment with either praziquantel or oxamniquine in Schistosoma mansoni infection.

Authors:  Takafira Mduluza; Francisca Mutapi; Tinashe Ruwona; Daniel Kaluka; Nicholas Midzi; Patricia D Ndhlovu
Journal:  Malawi Med J       Date:  2009-12       Impact factor: 0.875

Review 2.  Helminth infections and host immune regulation.

Authors:  Henry J McSorley; Rick M Maizels
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

3.  Cytokine profile, proliferation and phosphorylation of ERK1/2 and Akt in circulating mononuclear cells from individuals during the chronic intestinal phase of Schistosomiasis mansoni infection.

Authors:  Roberta Oliveira-Prado; Iramaya Rodrigues Caldas; Andréa Teixeira-Carvalho; Marcus Vinicius Andrade; Rafaelle Christine Gomes Fares; Laís Maroni Portugal; Andréa Gazzinelli; Rodrigo Corrêa-Oliveira; José Renan Cunha-Melo
Journal:  BMC Infect Dis       Date:  2012-12-27       Impact factor: 3.090

4.  Regulatory and activated T cells in human Schistosoma haematobium infections.

Authors:  Norman Nausch; Nicholas Midzi; Takafira Mduluza; Rick M Maizels; Francisca Mutapi
Journal:  PLoS One       Date:  2011-02-10       Impact factor: 3.240

5.  Schistosoma mansoni Larvae Do Not Expand or Activate Foxp3+ Regulatory T Cells during Their Migratory Phase.

Authors:  Stephen A Redpath; Nienke van der Werf; Andrew S MacDonald; Rick M Maizels; Matthew D Taylor
Journal:  Infect Immun       Date:  2015-07-20       Impact factor: 3.441

6.  CD4+CD25hiFOXP3+ Regulatory T Cells and Cytokine Responses in Human Schistosomiasis before and after Treatment with Praziquantel.

Authors:  Yvonne Schmiedel; Ghyslain Mombo-Ngoma; Lucja A Labuda; Jacqueline J Janse; Brechje de Gier; Ayôla A Adegnika; Saadou Issifou; Peter G Kremsner; Hermelijn H Smits; Maria Yazdanbakhsh
Journal:  PLoS Negl Trop Dis       Date:  2015-08-20

7.  Cytokine Pattern of T Lymphocytes in Acute Schistosomiasis mansoni Patients following Treated Praziquantel Therapy.

Authors:  Denise Silveira-Lemos; Matheus Fernandes Costa-Silva; Amanda Cardoso de Oliveira Silveira; Mauricio Azevedo Batista; Lúcia Alves Oliveira-Fraga; Alda Maria Soares Silveira; Maria Carolina Barbosa Alvarez; Olindo Assis Martins-Filho; Giovanni Gazzinelli; Rodrigo Corrêa-Oliveira; Andréa Teixeira-Carvalho
Journal:  J Parasitol Res       Date:  2013-01-20

8.  Cross-reactivity of commercially available anti-human monoclonal antibodies with canine cytokines: establishment of a reliable panel to detect the functional profile of peripheral blood lymphocytes by intracytoplasmic staining.

Authors:  Marcela L Moreira; Elaine M S Dorneles; Rodrigo P Soares; Camila P Magalhães; Christiane Costa-Pereira; Andrey P Lage; Andréa Teixeira-Carvalho; Olindo A Martins-Filho; Márcio S S Araújo
Journal:  Acta Vet Scand       Date:  2015-09-11       Impact factor: 1.695

9.  Impaired lymphocyte profile in schistosomiasis patients with periportal fibrosis.

Authors:  Luciana Santos Cardoso; Andréia de Souza Rocha Barreto; Jamille Souza Fernandes; Ricardo Riccio Oliveira; Robson da Paixão de Souza; Edgar M Carvalho; Maria Ilma Araujo
Journal:  Clin Dev Immunol       Date:  2013-11-18

10.  Schistosoma mansoni SmKI-1 or Its C-Terminal Fragment Induces Partial Protection Against S. mansoni Infection in Mice.

Authors:  Suellen B Morais; Barbara C Figueiredo; Natan R G Assis; Jane Homan; Fábio S Mambelli; Rodrigo M Bicalho; Cláudia Souza; Vicente P Martins; Carina S Pinheiro; Sergio C Oliveira
Journal:  Front Immunol       Date:  2018-07-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.